These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 16753016)

  • 1. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis.
    Ma YL; Zeng Q; Donley DW; Ste-Marie LG; Gallagher JC; Dalsky GP; Marcus R; Eriksen EF
    J Bone Miner Res; 2006 Jun; 21(6):855-64. PubMed ID: 16753016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.
    Arlot M; Meunier PJ; Boivin G; Haddock L; Tamayo J; Correa-Rotter R; Jasqui S; Donley DW; Dalsky GP; Martin JS; Eriksen EF
    J Bone Miner Res; 2005 Jul; 20(7):1244-53. PubMed ID: 15940379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
    Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
    J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium.
    Lindsay R; Zhou H; Cosman F; Nieves J; Dempster DW; Hodsman AB
    J Bone Miner Res; 2007 Apr; 22(4):495-502. PubMed ID: 17227219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Recker RR; Marin F; Ish-Shalom S; Möricke R; Hawkins F; Kapetanos G; de la Peña MP; Kekow J; Farrerons J; Sanz B; Oertel H; Stepan J
    J Bone Miner Res; 2009 Aug; 24(8):1358-68. PubMed ID: 19338452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide.
    Lindsay R; Cosman F; Zhou H; Bostrom MP; Shen VW; Cruz JD; Nieves JW; Dempster DW
    J Bone Miner Res; 2006 Mar; 21(3):366-73. PubMed ID: 16491283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.
    Recker RR; Bare SP; Smith SY; Varela A; Miller MA; Morris SA; Fox J
    Bone; 2009 Jan; 44(1):113-9. PubMed ID: 18983947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
    J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
    J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Ballaouri I; Efstathiadou Z; Kita M; Avramidis A
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of exercise training on bone remodeling, insulin-like growth factors, and bone mineral density in postmenopausal women with and without hormone replacement therapy.
    Milliken LA; Going SB; Houtkooper LB; Flint-Wagner HG; Figueroa A; Metcalfe LL; Blew RM; Sharp SC; Lohman TG
    Calcif Tissue Int; 2003 Apr; 72(4):478-84. PubMed ID: 12574871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.
    Chen P; Miller PD; Recker R; Resch H; Rana A; Pavo I; Sipos AA
    J Bone Miner Res; 2007 Aug; 22(8):1173-80. PubMed ID: 17451369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure.
    Jiang Y; Zhao JJ; Mitlak BH; Wang O; Genant HK; Eriksen EF
    J Bone Miner Res; 2003 Nov; 18(11):1932-41. PubMed ID: 14606504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.